Hospital Mater DeiBSP:MATD3 +2.98%83 Return-on-Tangible-Equity is 17.68% as of Mar. 2026, which is 1% above its 10-year median of 17.52. GuruFocus rates BSP:MATD3 with a GF Score™ of 83/100 and a GF Value™ of R$5.88 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Hospital Mater Dei ranks better than 63.21% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hospital Mater Dei's annualized net income for the quarter that ended in Mar. 2026 was R$133 Mil. Hospital Mater Dei's average shareholder tangible equity for the quarter that ended in Mar. 2026 was R$751 Mil. Therefore, Hospital Mater Dei's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 17.68%.
The historical rank and industry rank for Hospital Mater Dei's Return-on-Tangible-Equity or its related term are showing as below:
BSP:MATD3'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -130.15 Med: 17.52 Max: 88.02
Current: 16.82
During the past 9 years, Hospital Mater Dei's highest Return-on-Tangible-Equity was 88.02%. The lowest was -130.15%. And the median was 17.52%.
BSP:MATD3's Return-on-Tangible-Equity is ranked better than 63.21% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.21
vs BSP:MATD3: 16.82
Hospital Mater Dei (BSP:MATD3) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Hospital Mater Dei Return-on-Tangible-Equity Related Terms
Hospital Mater Dei Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Hospital Mater Dei's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hospital Mater Dei Return-on-Tangible-Equity Chart
BSP:MATD3 vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Hospital Mater Dei's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hospital Mater Dei Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Hospital Mater Dei's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Hospital Mater Dei's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.68% mean?
Hospital Mater Dei (BSP:MATD3) has a Return-on-Tangible-Equity of 17.68% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hospital Mater Dei and its competitors. This is near median its historical median of 17.52. According to the industry distribution chart, Hospital Mater Dei ranks #213 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 36.8%.
Is Hospital Mater Dei's Return-on-Tangible-Equity too high?
Hospital Mater Dei's current Return-on-Tangible-Equity of 17.68% is near median its 10-year median of 17.52. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.21. Hospital Mater Dei's value of 17.68% is 73.2% above this industry median. Based on the distribution chart, Hospital Mater Dei ranks #213 out of 579 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Hospital Mater Dei has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hospital Mater Dei's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Hospital Mater Dei ranks #213 out of 579 companies for Return-on-Tangible-Equity. This puts Hospital Mater Dei in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.21. Hospital Mater Dei's value of 17.68% is 73.2% above this benchmark. While the company's 10-year median is 17.52 vs. the industry median of 10.21, Hospital Mater Dei has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.21, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hospital Mater Dei's current Return-on-Tangible-Equity of 17.68% is 73.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Hospital Mater Dei and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hospital Mater Dei's current Return-on-Tangible-Equity is 17.68%, which is near median its own 10-year median of 17.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hospital Mater Dei stock overvalued right now?
Based on GuruFocus' analysis, Hospital Mater Dei (BSP:MATD3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$5.88, compared to a current price of R$4.84 — trading 17.7% below its estimated fair value. The current Return-on-Tangible-Equity is 17.68%, which is near median its 10-year median of 17.52 and 73.2% above the Healthcare Providers & Services industry median of 10.21. Hospital Mater Dei's overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Hospital Mater Dei (BSP:MATD3), the current Return-on-Tangible-Equity is 17.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hospital Mater Dei (BSP:MATD3) Overvalued in 2026?
Based on GuruFocus' analysis, Hospital Mater Dei stock appears to be undervalued.
The current stock price of R$4.84 is trading 17.7% below its estimated GF Value™ of R$5.88.
GuruFocus considers Hospital Mater Dei to be Modestly Undervalued.
Key valuation signals for BSP:MATD3:
Return-on-Tangible-Equity: 17.68% (near median its 10-year median of 17.52)
GF Value™: R$5.88 vs. price of R$4.84 (17.7% below fair value)
Industry Position: 73.2% above the Healthcare Providers & Services median (#213 of 579)
No single metric tells the full story. See the BSP:MATD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hospital Mater Dei SA is an integrated healthcare ecosystem that provides hospital and oncological services. The company provides a wide range of healthcare services, including hospitalizations, surgeries, oncology treatments, medical appointments, and diagnostic exams.
83GF Score
Get the complete analysis for BSP:MATD3
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:MATD3 has been successfully added to your 
